您的账号已在其他设备登录,您当前账号已强迫下线,
如非您本人操作,建议您在会员中心进行密码修改

确定

英夫利昔单抗在儿童炎症性肠病中的应用

Application of Infliximab on inflammatory bowel disease in children

摘要:

炎症性肠病是一种慢性的非特异性肠道疾病,其治疗方法主要以药物为主。目前英夫利昔单抗(IFX)是唯一应用于我国炎症性肠病患儿的生物制剂,本质上是生物合成的人鼠嵌合性单克隆抗体,能够与T淋巴细胞上的肿瘤坏死因子α(TNF-α)相结合,通过细胞毒作用和诱导淋巴细胞凋亡来抑制炎性反应。IFX可以达到有效的短期诱导缓解和长期维持缓解症状,同时具有促进黏膜修复、改善患儿生存质量及减少并发症的作用。临床研究中也发现存在一部分对IFX治疗反应差或无效的病例。另外由于生物制剂高昂的成本,生物仿制药正逐渐开始研发与应用。现就IFX在儿童炎症性肠病中的应用进行综述。

更多
abstracts:

Inflammatory bowel disease is a chronic and nonspecific intestinal disease that is mainly treated with drugs.At present, Infliximab (IFX) is the only biological agent applied for children with inflammatory bowel disease in China.It is essentially a biosynthetic chimeric monoclonal antibody, and can be combined with tumor necrosis factor-alpha(TNF-α) on T cells inhibition of inflammatory response through cytotoxicity and induction of lymphocyte apoptosis.IFX can induce remission in the short term and maintain remission in the long term.It can also promote mucosal repair, improve the quality of life and reduce complications.Clinical studies revealed that there were a proportion of patients who respond poorly or ineffectively to IFX treatment.Furthermore, due to the high cost of biological agents, bio generic drugs are gradually starting to be developed and applied.This article provided an overview of the application of IFX on inflammatory bowel disease in children.

More
作者: 冯百慧 [1] 许玲芬 [1]
期刊: 《中华实用儿科临床杂志》2020年35卷19期 1514-1517页 ISTICPKUCA
栏目名称: 综述
DOI: 10.3760/cma.j.cn101070-20191116-01139
发布时间: 2020-11-09
  • 浏览:23
  • 下载:24

加载中!

相似文献

  • 中文期刊
  • 外文期刊
  • 学位论文
  • 会议论文

加载中!

加载中!

加载中!

加载中!